trending Market Intelligence /marketintelligence/en/news-insights/trending/wlVBFfKsNa12FqkcW23yFw2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

MacroGenics, Synthon Biopharmaceuticals partner on solid tumor targeting drug

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


MacroGenics, Synthon Biopharmaceuticals partner on solid tumor targeting drug

MacroGenics Inc. and Synthon Biopharmaceuticals BV entered a license and collaboration agreement for the development of MGC018, an antibody-drug conjugate directed against solid tumors.

The drug is based on MacroGenics' proprietary B7-H3 antibody and Synthon's proprietary duocarmycin-based, linker-drug technology.

Under the agreement, Synthon has licensed rights to its linker-drug technology to MacroGenics to enable future development and commercialization of MGC018.

Synthon will also provide manufacturing support and supply the antibody-drug conjugate to MacroGenics and will be entitled to receive license fees, milestone payments and royalties based on successful development and commercialization of the drug.